Close menu




November 8th, 2019 | 07:50 CET

BMW, NEL ASA, IWATER GROUP - TODAY RECOGNIZE THE TOPICS OF THE FUTURE

  • Innovations
Photo credits: pixabay.com

This week, the German government decided to create incentives to buy e-mobility with higher subsidies. For example, government support for the purchase of a new car was increased from EUR 4,000 to EUR 6,000. The large car batteries of the electric cars, however, can lead to an extended problem of electronic scrap at landfills all over the world due to a lack of recycling methods and infrastructure if solutions are not worked out at the same time.

time to read: 2 minutes | Author: Mario Hose
ISIN:

Table of contents:


    WHO WILL BUY BATTERY CARS?

    The carmakers BMW, Daimler and Volkswagen have politicians on their side for more support to drive the electromobility project forward. The current sales figures for battery cars are sober. Despite all the marketing measures, according to the Federal Motor Transport Authority, 47,903 battery-powered cars were registered in Germany in the first nine months of 2019, which corresponds to just 1.7% of the total number of 2,740,158 passenger cars. Battery cars are expected to play a role in the future mobility mix, but no technology is free.

    WHO TAKES CARE OF ELECTRONIC SCRAP?

    The lithium-ion batteries used to power electric cars of all kinds are made of metals that are degraded under considerable environmental and human stress and do not last forever. For example, with a low battery weight of 250 kilograms, 1,000,000 cars generate an additional 250,000 tons of waste. Powerful vehicles like the Tesla S have batteries weighing over 700 kilograms on board.

    WHO BEARS THE COSTS OF RECYCLING?

    The batteries of the various battery manufacturers have different standards, which does not make recycling any easier. It is also important to bear the costs, because recycling will become costly. Before we get there, there is another important question: Where should all the raw materials for the batteries come from? The annual demand for lithium is expected to exceed the current production rates from the mines as early as 2022 and by 2050 the demand for cobalt could exceed the known planetary reserves.

    WHEN WILL THE HYDROGEN FILLING STATION NETWORK BE IN PLACE?

    A real alternative to a purely battery-powered vehicle is the fuel cell. The refuelling process in connection with hydrogen technology is comparable with petrol and diesel on the basis of duration and range. In Germany there is a nationwide network of around 14,000 filling stations offering petrol and diesel.

    A similar number of hydrogen filling stations will probably be sufficient to make hydrogen technology socially acceptable. A much smaller number compared to millions of charging stations for battery cars. The Norwegian company NEL ASA develops devices for the production of hydrogen and thus plays an interesting role in connection with the development of a filling station network for this energy carrier.

    WHO CLEANS WATER IN AN ENVIRONMENTALLY FRIENDLY WAY?

    The waste product of the fuel cell is water, and iWater Group Limited is also concerned with this future topic. With its products and processes, the company focuses on the purification of contaminated water. According to the company, products have been used worldwide in agriculture, food processing, livestock farming and oil & gas since 2018. Since then, they have ensured environmentally compatible purification of water and a reduction in the use of antibiotics and pesticides.

    Last month, the former CEO of Kühne + Nagel, Reinhard Lange, was appointed to the company's Executive Board with responsibility for Globalization & Logistics. Water, the staple food, will gain in importance and the topic of cleaning will continue to occupy us more in the future.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by André Will-Laudien on September 8th, 2026 | 09:40 CEST

    Biotech: Time to Bet on the Rebound! Evotec and BioNxt in the Takeover Spotlight, Bayer and BioNTech Flush with Cash

    • Biotech
    • Biotechnology
    • Innovations
    • Takeover
    • rebound

    After a long dry spell, the biotech sector is on the cusp of a spectacular turnaround, offering bold investors the potential for significant returns. Many innovative biotech stocks are trading well below their all-time highs, yet almost unnoticed, the next major rally is already taking shape behind the scenes. The huge cash reserves of industry giants Bayer and BioNTech are currently fueling takeover speculation across the sector. This colossal capital, running into the billions, is desperately seeking new growth drivers, suddenly putting smaller players on the radar of potential acquirers. At the very top of the hunters' watchlist are the hard-hit Evotec and the disruptive newcomer BioNxt. Both companies boast top-class technology platforms, which, at current levels, almost seem like an exclusive clearance sale. Investors who keep their eyes open and position themselves strategically for the major rebound could get ahead of the looming wave of consolidation. The conditions for an explosive catch-up rally have rarely been this favorable.

    Read

    Commented by Fabian Lorenz on September 1st, 2026 | 07:45 CEST

    Potential Moderna-Style Share Surge? Takeover Candidates Evotec, Valneva and Vidac Pharma in Focus — Analysts Bullish

    • Biotechnology
    • Pharma
    • Innovations
    • Oncology

    Moderna has shaken up the biotech market with its breakthrough in the fight against skin cancer. Partner Merck has received somewhat less attention in the coverage, despite preparing for the eventual patent expiration of one of its blockbuster drugs. Other pharmaceutical companies will also need to replenish their pipelines in the coming years. As a result, the takeover merry-go-round is likely to pick up speed again, potentially electrifying investors. One hot candidate is Vidac Pharma. Recruitment for its Phase 2B trial into high-risk actinic keratosis, a precancerous skin condition, has been completed. The results could provide a catalyst for the stock. Valneva's share price has recently risen sharply. Could its partner Pfizer eventually make a move? Analysts are recommending the stock. And what about perennial takeover candidate Evotec? Shareholders and potential buyers are currently giving the share a wide berth. Yet there is a "Buy" recommendation on the table.

    Read

    Commented by Tarik Dede on August 17th, 2026 | 07:55 CEST

    Cancer in Focus: Merck & Co., Vidac Pharma and AstraZeneca

    • Biotechnology
    • Biotech
    • Cancer
    • Innovations
    • Pharma
    • patents

    According to the International Agency for Research on Cancer (IARC), part of the WHO, there are currently around 20.6 million new cancer cases worldwide. The annual death toll is estimated at approximately 10 million people. In recent years, more than 53 million people globally have received a cancer diagnosis. According to the WHO, the number of new cases per year is expected to rise to about 35 million by 2050. Two factors are generally cited as the main drivers: demographic change, with the global population getting older, as well as rising rates of obesity, physical inactivity, smoking and air pollution in many countries. Unsurprisingly, the oncology market is correspondingly lucrative. Oncology is the world's largest pharmaceutical market. There is, however, also some good news: the age-adjusted risk of dying from cancer is declining thanks to earlier detection, targeted therapies and advances in immuno-oncology. Today, we take a closer look at this market through the stocks of Merck & Co., Vidac Pharma and AstraZeneca.

    Read